Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsTakehisa Kitazawa, Kunihiro Hattori
Life of this patent
Estimating the term…
Abstract
Formulations for neutralizing the anticoagulant action of a human tissue factor inhibitor, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient; and formulations for neutralizing the blood coagulation-promoting action of an activated blood coagulation factor VII product, comprising a human tissue factor inhibitor as an active ingredient.
Claims36
A formulation for neutralizing the anticoagulant action of a human tissue factor inhibitor, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient.
A formulation for suppressing the bleeding or bleeding tendency caused by a human tissue factor inhibitor, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient.
A formulation for neutralizing the blood coagulation time (prothrombin time) prolonging action caused by a human tissue factor inhibitor, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient.
A formulation for suppressing bleeding or bleeding tendency, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient, characterized in that it is administered simultaneously with a human tissue factor inhibitor or after administering a human tissue factor inhibitor.
An antithrombotic agent comprising a human tissue factor inhibitor and a blood coagulation factor complex product or an activated blood coagulation factor VII product.
A pharmaceutical kit comprising a human tissue factor inhibitor and a blood coagulation factor complex product or an activated blood coagulation factor VII product.
A formulation for suppressing the blood coagulation-promoting action of an activated blood coagulation factor VII product, comprising a human tissue factor inhibitor as an active ingredient.
A formulation for suppressing the thrombosis or hypercoagulable states caused by an activated blood coagulation factor VII product, comprising a human tissue factor inhibitor as an active ingredient.
A formulation for neutralizing the blood coagulation time (prothrombin time) shortening action caused by an activated blood coagulation factor VII product, comprising a human tissue factor inhibitor as an active ingredient.
A formulation for suppressing thrombosis or hypercoagulable states, comprising a human tissue factor inhibitor as an active ingredient, characterized in that it is administered simultaneously with an activated blood coagulation factor VII product or after administering an activated blood coagulation factor VII product.
A hemostatic agent comprising an activated blood coagulation factor VII product and a human tissue factor inhibitor.
A method for neutralizing the anticoagulant action of a human tissue factor inhibitor, comprising administering a blood coagulation factor complex product or an activated blood coagulation factor VII product.
A method for suppressing the bleeding or bleeding tendency caused by a human tissue factor inhibitor, comprising administering a blood coagulation factor complex product or an activated blood coagulation factor VII product.
A method for neutralizing the blood coagulation time (prothrombin time) prolonging action caused by a human tissue factor inhibitor, comprising administering a blood coagulation factor complex product or an activated blood coagulation factor VII product.
A method for suppressing bleeding or bleeding tendency, comprising administering a blood coagulation factor complex product or an activated blood coagulation factor VII product, characterized in that it is administered simultaneously with a human tissue factor inhibitor or after administering a human tissue factor inhibitor.
A method for treating thrombosis, comprising administering a human tissue factor inhibitor and a blood coagulation factor complex product or an activated blood coagulation factor VII product.
A method for suppressing the blood coagulation-promoting action of an activated blood coagulation factor VII product, comprising administering a human tissue factor inhibitor.
A method for suppressing the thrombosis or hypercoagulable states caused by an activated blood coagulation factor VII product, comprising administering a human tissue factor inhibitor.
A method for neutralizing the blood coagulation time (prothrombin time) shortening action caused by an activated blood coagulation factor VII product, comprising administering a human tissue factor inhibitor.
A method for suppressing thrombosis or hypercoagulable states, comprising administering a human tissue factor inhibitor, characterized in that it is administered simultaneously with an activated blood coagulation factor VII product or after administering an activated blood coagulation factor VII product.
A method for stopping bleeding, comprising administering an activated blood coagulation factor VII product and a human tissue factor inhibitor.
Dependencies are inferred from the claim text.